百利天恒(688506) - 2024 Q4 - 年度业绩

Financial Performance - The company achieved total operating revenue of 582,271.78 million yuan, a year-on-year increase of 936.31%[4] - The net profit attributable to the parent company was 365,793.43 million yuan, an increase of 443,843.32 million yuan compared to the same period last year[5] - The net profit attributable to the parent company after deducting non-recurring gains and losses was 360,364.96 million yuan, an increase of 441,639.83 million yuan year-on-year[5] - The basic earnings per share reached 9.12 yuan, compared to a loss of 1.95 yuan in the previous year[4] - The weighted average return on net assets was 184.67%, a significant improvement from -143.57% in the previous year[4] Assets and Equity - The total assets at the end of the reporting period were 710,617.49 million yuan, reflecting a growth of 398.64% from the beginning of the year[5] - The equity attributable to the parent company increased by 2,416.25% to 382,151.15 million yuan[5] - The company's net assets per share attributable to the parent company increased to 9.53 yuan, up 2,407.89% from the previous year[4] Strategic Partnerships and Investments - The company received an irrevocable and non-deductible upfront payment of 800 million USD from its overseas partner Bristol-Myers Squibb (BMS) for its core product BL-B01D1[5] - The company plans to continue focusing on strategic areas and increasing R&D investment to advance the development of innovative biopharmaceuticals[5]